#3: Recent Anti-Infective Trials Reviewed at ID Week 2017
Clinical trials are a linchpin of clinical science. They are designed to evaluate the prowess of an antibacterial, antifungal, and antiviral compounds. The busy clinical trial terrain results in a barrage of data. Sifting through all this information to discover studies that describe drugs that are practice-changing can be challenging for a busy clinician.
A session at the year’s ID Week in San Diego, California came to the rescue. The speakers were tasked with summarizing recent important clinical trials involving viruses, bacteria, and fungi. Francisco Marty, MD, Division of Infectious Diseases, Brigham and Women's Hospital, Boston, Massachusetts, reviewed recent antiviral trials, excepting those involving HIV. His focus was the herpes zoster subunit vaccine, intravenous (IV) influenza drugs, and letermovir for prevention of post-transplant cytomegalovirus (CMV) infection.
Read more about anti-infective trials presented at ID Week here
#2: Nearly 10% of Americans with Candidemia have Clostridium difficile Co-infection
A survey of Americans hospitalized for treatment of candidemia has revealed the presence of Clostridium difficile
) co-infection in almost 10% of the cases.
Infections caused by C. difficile
species are important healthcare-associated infections. A multistate survey carried out in 2014 by the US Centers for Disease Control and Prevention (CDC) reported C. difficile
in 61 of 504 (12.1%) and 32 of 504 (6.3%) infections, with C. difficile
responsible for 70% of all recorded gastrointestinal infections and Candida
responsible for 22% of all bloodstream infections. Both infections carry a high mortality rate.
Read more about Candida